Deals & Cases

Santhera Enters into Option and Sublicense Agreement with Idorsia

22.11.2018

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare and other diseases with high unmet medical needs. On 20 November 2018, Santhera Pharmaceuticals announced that it had entered into an agreement with Idorsia Ltd (SIX: IDIA) under which Santhera will acquire the option to exclusively in-license, by way of sublicense, the steroid vamorolone in all indications and all countries worldwide except Japan and South Korea. Vamorolone is a highly promising drug candidate for the treatment of patients with Duchenne muscular dystrophy.

Schellenberg Wittmer advised Santhera Pharmaceuticals on this matter.

The team was led by Philipp Groz (IP / Life Sciences) and included Marcel Jakob (Corporate/M&A).

 

Subscribe to our Updates

*Required fields

Monthly selected key topics from our practice areas and sectors, plus Newsflashes on current events.
Monthly email with the latest updates on and summaries of the Swiss Federal Supreme Court's case law in arbitration matters.
A regular look (1 – 2 per year) from a unique M&A perspective on legal changes, economic developments and societal trends in Switzerland.
Regular insights on Swiss and international trends and legal developments in the construction industry.
Concise analyses of key trends in the fast moving world of corporate governance for the boards of Swiss companies.